- 2Q 2017 revenue of $483 million
-
Net income from continuing operations of $28 million
- Net income from continuing operations per diluted share of $0.19
- 2Q 2017 Adjusted EBITDA of $94 million
-
Adjusted net income from continuing operations of $29 million
- Adjusted net income from continuing operations per diluted share of $0.20
DURHAM, N.C.--(BUSINESS WIRE)--Patheon N.V. (NYSE: PTHN), a leading global provider of pharmaceutical development and manufacturing services, today reported financial results for the quarter ended April 30, 2017.
Second quarter 2017 revenue was $483 million, compared to $469 million in the prior-year period, and second quarter 2017 adjusted EBITDA was $94 million, compared to $98 million in the prior-year period. Revenue for the first six months of fiscal 2017 was $941 million, compared to $875 million in the comparable fiscal 2016 period, representing 8% year-over-year growth. Adjusted EBITDA for the first six months of fiscal 2017 was $177 million, compared to $157 million in the comparable fiscal 2016 period, representing 13% year-over-year growth.
“During the second quarter we continued to build momentum with customers and make strategic investments to support our long-term growth outlook,” said Patheon CEO, Jim Mullen. “Looking forward, we believe the announced sale to Thermo Fisher is a logical next step in the evolution of our company and is in the best interests of all stakeholders. Together, both companies will be better positioned to add scale and new value chain capabilities, delivering even greater value to customers.”
Second quarter 2017 net income from continuing operations was $28 million. Second quarter 2017 net income from continuing operations per diluted share was $0.19.
Second quarter 2017 adjusted net income from continuing operations was $29 million. Second quarter 2017 adjusted net income from continuing operations per diluted share was $0.20.
Second Quarter and YTD 2017 Segment Highlights
